Results 171 to 180 of about 51,530 (306)
Autoimmune Encephalitis—Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes [PDF]
Katarzyna D. Bera+2 more
openalex +1 more source
Abstract Objective This study was undertaken to describe a case series of Brazilian new onset refractory status epilepticus (NORSE) patients and evaluate the sensitivity and specificity of a clinical score to predict cryptogenic etiology (c‐NORSE score) after autoimmune encephalitis (AE) testing.
João Henrique Fregadolli Ferreira+42 more
wiley +1 more source
Identification and Characterization of GABAA Receptor Autoantibodies in Autoimmune Encephalitis [PDF]
Toshika Ohkawa+9 more
openalex +1 more source
Abstract Objective Following emerging evidence of autoimmune‐associated seizures in medication‐refractory epilepsy, we began offering a trial of immunotherapy to selected patients. Here, we review this approach's treatment response, predictive clinical features, and utility.
Elisabeth Doran+4 more
wiley +1 more source
Evaluation of Incidence and Clinical Features of Antibody-Associated Autoimmune Encephalitis Mimicking Dementia [PDF]
Arzu Çoban+12 more
openalex +1 more source
Trajectories of long‐term survival after status epilepticus
Abstract Objectives To investigate the trajectories of clinical characteristics and prognostic factors among long‐term survivors of status epilepticus (SE), given the high mortality during acute hospitalization and in subsequent years. Methods Adult patients (≥18 years of age) with first‐time, non‐anoxic SE were identified and included from University ...
Camilla Dyremose Cornwall+8 more
wiley +1 more source
Screening Autoimmune Anti-neuronal Antibodies in Pediatric Patients with Suspected Autoimmune Encephalitis [PDF]
Soo Yeon Kim+12 more
openalex +1 more source
Abstract Objective We aimed to investigate whether the risk of unprovoked seizures differs between patients receiving a brief antiseizure medication (ASM) course during hospitalization and those treated beyond hospital discharge following acute symptomatic seizures (ASyS).
Vineet Punia+7 more
wiley +1 more source
Open‐label CBD treatment was associated with sustained seizure reduction through 144 weeks, with a consistent safety profile in patients with treatment‐resistant focal epilepsies, regardless of epilepsy type. Abstract Objective Cannabidiol (CBD) treatment was associated with long‐term seizure reduction in patients with various treatment‐resistant ...
Anup D. Patel+8 more
wiley +1 more source